Future Directions in Anxiety Research
More than 3.5 million patients suffer from anxiety in the United States of America alone. While our knowledge of the basic biological mechanisms of anxiety is very poor, we have a good understanding of the mechanism of action of various anxiolytic drugs at the molecular level. Their mechanism of action often relates to the inhibitory neurotransmitter GABA and it might be speculated that GABA has a role in anxiety. Future research will concentrate on designing better anxiolytic drugs, based for example on the discovery of partial benzodiazepine receptor agonists, and also on GABA uptake inhibitors as enhancers of GABAergic function. Furthermore, scientific studies will focus on a search for putative biological defects related to anxiety, such as defects in the GABA/benzodiazepine receptor chloride channel complex.
KeywordsDopamine Dementia Schizophrenia Choline Diazepam
Unable to display preview. Download preview PDF.
- Bræstrup C, Nielsen M (1983) Benzodiazepine receptors. In: Iversen L, Iversen DS, Snyder SH (eds) Handbook of psychopharmacology, vol 17. Plenum, New York, pp 285–384Google Scholar
- Falch E, Christensen V, Jacobsen P, Bybjerg J, Krogsgaard-Larsen P (1984) Amanita muscaria in medicinal chemistry. I. Muscimol and related GABA agonists with anticonvulsant and central non-opioid analgesic effects. In: Krogsgaard-Larsen P, Christensen SB, Kofod H (eds) Natural products and drug development. Munksgaard, Copenhagen, pp 504–524Google Scholar
- Haefely W, Kulcsâr A, Moehler H, Pieri L, Pole P, Schaffner R (1975) Possible involvement of GABA in the central actions of benzodiazepines. In: Costa E, Greengard P (eds) Mechanism of action of benzodiazepines. Raven, New York, pp 131–151Google Scholar
- Younger LM, Fowler PJ, Zarevics P, Setler PE (1984) Novel inhibitors of γ-aminobutyric acid (GABA) uptake: anticonvulsant actions in rats. J Pharmacol Exp Ther 228: 109–115Google Scholar